Genetic mechanisms of antimicrobial resistance of Acinetobacter baumannii

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 218-228

  Esterly, John S ^a,b   Richardson, Chad L ^b   Eltoukhy, Noha S ^c   Qi, Chao ^b,d   Scheetz, Marc H ^b,e  

^a CHICAGO STATE UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c St Mary Medical Center Langhorne   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MIDWESTERN UNIVERSITY   (United States)

Author keywords

lactamases; Acinetobacter baumannii; Antibiotics; Genetic mechanisms; Resistance

Indexed keywords

ACYLTRANSFERASE; AMIKACIN; AZTREONAM; BETA LACTAMASE CTX M; BETA LACTAMASE IMP; BETA LACTAMASE KPC; BETA LACTAMASE SHV; BETA LACTAMASE SIM; BETA LACTAMASE TEM 1; BETA LACTAMASE VIM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METALLO BETA LACTAMASE; NUCLEOTIDYLTRANSFERASE; PHOSPHOTRANSFERASE; POLYMYXIN; PORIN; PROTEIN PARC; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; CELL MEMBRANE; GENOTYPE; HUMAN; INTEGRON; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSPOSON; DRUG EFFECTS; GENETICS; MUTATION;

ACINETOBACTER BAUMANNII; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; MACROLIDES; MUTATION; POLYMYXINS; TETRACYCLINES;

EID: 79951906190     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P084     Document Type: Review

References (126)

1. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007;26:793-800. DOI 10.1007/s10096-007-0371-8 (Pubitemid 47573383)
2. Robenshtok E, Paul M, Leibovici L, et al. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006;64:282-7. DOI 10.1016/j.jhin.2006.06.025 (Pubitemid 44480714)
3. Kwon KT, Oh WS, Song JH, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525-30. DOI 10.1093/jac/dkl499 (Pubitemid 47073460)
4. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006;10:R48. DOI 10.1186/cc4869
5. Naas T, Namdari F, Reglier-Poupet H, Poyart C, Nordmann P. Panresistant extended-spectrum beta-lactamase SHV-5-producing Acinetobacter baumannii from New York City. J Antimicrob Chemother 2007;60: 1174-6. DOI 10.1093/jac/dkm366 (Pubitemid 47617776)
6. Rossolini GM, Mantengoli E, Docquier JD, Musmanno RA, Coratza G. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol 2007;30:332-9. (Pubitemid 47264901)
7. Saleem AF, Ahmed I, Mir F, Ali SR, Zaidi AK. Pan-resistant Acinetobacter infection in neonates in Karachi, Pakistan. J Infect Dev Ctries 2009;4:30-7.
8. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009;3:335-41.
9. Agodi A, Auxilia F, Barchitta M, et al. Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI. J Hosp Infect 2010;74:258-65. DOI 10.1016/j.jhin.2009.08.015
10. Lin MF, Yang CM, Lin CH, Huang ML, Tu CC, Liou ML. Clinical features and molecular epidemiology of multidrug-resistant Acinetobacter calcoaceticus- A baumannii complex in a regional teaching hospital in Taiwan. Am J Infect Control 2009;37:e1-3. DOI 10.1016/j.ajic.2009.03.008
11. Neely AN. A survey of gram-negative bacteria survival on hospital fabrics and plastics. J Burn Care Rehabil 2000;21:523-7. (Pubitemid 32050418)
12. Webster C, Towner KJ, Humphreys H. Survival of Acinetobacter on three clinically related inanimate surfaces. Infect Control Hosp Epidemiol 2000;21:246. DOI 10.1086/503214
13. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997;35:1394-7. (Pubitemid 27216802)
14. Bernards AT, van der Toorn J, van Boven CP, Dijkshoorn L. Evaluation of the ability of a commercial system to identify Acinetobacter genomic species. Eur J Clin Microbiol Infect Dis 1996;15:303-8. (Pubitemid 26159691)
15. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991;29:277-82.
16. Qi C, Malczynski M, Parker M, Scheetz MH. Characterization of genetic diversity of carbapenem-resistant Acinetobacter baumannii clinical strains collected from 2004 to 2007. J Clin Microbiol 2008;46:1106-9. DOI 10.1128/JCM.01877-07
17. D'Arezzo S, Capone A, Petrosillo N, et al. Epidemic multidrug-resistant Acinetobacter baumannii related to European clonal types I and II in Rome (Italy). Clin Microbiol Infect 2009;15:347-57.
18. Park YK, Choi JY, Jung SI, et al. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis 2009;64:389-95. DOI 10.1016/j.diagmicrobio.2009.03. 029
19. Zhou H, Yang Q, Yu YS, Wei ZQ, Li LJ. Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China. J Clin Microbiol 2007;45:4054-7. DOI 10.1128/JCM.00343-07 (Pubitemid 350274894)
20. Qi C, Scheetz MH, Malczynski M. Characterization of Acinetobacter baumannii genotypes recovered from patients with repeated colonization or infection. Diagn Microbiol Infect Dis 2009;65:1-6. DOI 10.1016/j.diagmicrobio. 2009.04.011
21. Sefton AM. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs 2002;62:557-66. (Pubitemid 34264025)
22. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82. DOI 10.1128/CMR.00058-07
23. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
24. Fournier PE, Vallenet D, Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2:e7. DOI 10.1371/journal.pgen.0020007
25. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009;63:426-33. DOI 10.1016/j.diagmicrobio.2009.01.026
26. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57: 207-15. DOI 10.1016/j.diagmicrobio. 2006.07.009
27. Pfaller MA, Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of cefepime tested against ceftazidime-resistant gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2006;56:63-8. DOI 10.1016/j.diagmicrobio.2006.02.009
28. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(suppl 2):S49-56. DOI 10.1086/504477
29. Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11:15-23. DOI 10.1111/j.1469-0691.2004.01016.x (Pubitemid 40227817)
30. Bou G, Martinez-Beltran J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000;44:428-32. (Pubitemid 30060746)
31. Heritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin Microbiol Infect 2006;12:123-30. DOI 10.1111/j.1469-0691.2005.01320.x (Pubitemid 43379339)
32. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003;52:629-35. DOI 10.1093/jac/dkg407 (Pubitemid 37258424)
33. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22:161-82. DOI 10.1128/CMR.00036-08
34. Galleni M, Amicosante G, Frere JM. A survey of the kinetic parameters of class C beta-lactamases, cephalosporins and other beta-lactam compounds. Biochem J 1988;255:123-9.
35. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-32. (Pubitemid 24343197)
36. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51. (Pubitemid 23036450)
37. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004;38:1449-59. DOI 10.1345/aph.1D592 (Pubitemid 39100202)
38. Yang Y, Rasmussen BA, Shlaes DM. Class A beta-lactamases - enzyme-inhibitor interactions and resistance. Pharmacol Ther 1999;83:141-51. (Pubitemid 29438599)
39. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-6. DOI 10.1016/j.jinf.2008.04.002
40. Huang ZM, Mao PH, Chen Y, Wu L, Wu J. [Study on the molecular epidemiology of SHV type beta-lactamase-encoding genes of multipledrug- resistant Acinetobacter baumannii]. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25:425-7.
41. Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol 2004;42:3978-84. DOI 10.1128/JCM.42.9.3978- 3984.2004 (Pubitemid 39296113)
42. Endimiani A, Luzzaro F, Migliavacca R, et al. Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended- spectrum beta-lactamase. Antimicrob Agents Chemother 2007; 51:2211-4. DOI 10.1128/AAC.01139-06 (Pubitemid 46903120)
43. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498-504. DOI 10.1128/AAC.50.2.498-504.2006 (Pubitemid 43190958)
44. Gavin PJ, Suseno MT, Thomson RB Jr, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended- spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006;50:2244-7. DOI 10.1128/AAC.00381-05 (Pubitemid 43807556)
45. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother 2010;11:779-88. DOI 10.1517/14656561003596350
46. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010;54:969-76. DOI 10.1128/AAC.01009-09
47. Chu YW, Afzal-Shah M, Houang ET, et al. IMP- 4, a novel metallo-betalactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001;45:710-4.
48. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003;9:868-71. (Pubitemid 36801591)
49. Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. Appearance of IMP-1 metallo-beta-lactamase in Europe. Lancet 1999;353:899-900.
50. Tognim MC, Gales AC, Penteado AP, Silbert S, Sader HS. Dissemination of IMP-1 metallo-beta-lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect Control Hosp Epidemiol 2006;27:742-7. (Pubitemid 44271957)
51. Tsakris A, Ikonomidis A, Pournaras S, et al. VIM-1 metallo-beta-lactamase in Acinetobacter baumannii. Emerg Infect Dis 2006;12:981-3.
52. Gales AC, Tognim MC, Reis AO, Jones RN, Sader HS. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. Diagn Microbiol Infect Dis 2003;45:77-9. (Pubitemid 36165034)
53. Lee K, Yum JH, Yong D, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother 2005;49: 4485-91. DOI 10.1128/AAC.49.11.4485-4491.2005 (Pubitemid 41552576)
54. Robledo IE, Aquino EE, Sante MI, et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 2010;54:1354-7. DOI 10.1128/AAC.00899-09
55. Adams-Haduch JM, Paterson DL, Sidjabat HE, et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008;52:3837-43. DOI 10.1128/AAC.00570-08
56. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006;50:2941-5. (Pubitemid 44396395)
57. Esterly JS, Qi C, Malczynski M, Scheetz MH. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy 2010;30:354-60. DOI 10.1592/phco.30.4.354
58. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36. DOI 10.1111/j.1469-0691.2006.01456.x (Pubitemid 44151282)
59. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000;44:1556-61. (Pubitemid 30340794)
60. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1530-3. (Pubitemid 46586845)
61. Bogaerts P, Naas T, Wybo I, et al. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA- 58 in Belgium. J Clin Microbiol 2006;44:4189-92. (Pubitemid 44737268)
62. Bertini A, Giordano A, Varesi P, Villa L, Mancini C, Carattoli A. First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrob Agents Chemother 2006;50:2268-9. (Pubitemid 43807563)
63. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:3198-202. DOI 10.1128/AAC.49.8.3198-3202.2005 (Pubitemid 41060561)
64. Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P. In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA- 66) oxacillinase gene. Antimicrob Agents Chemother 2009;53:2657-9. DOI 10.1128/AAC.01663-08
65. Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006;258:72-7.
66. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:4174-9. DOI 10.1128/AAC.49.10. 4174-4179.2005 (Pubitemid 41400961)
67. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006;57:1-3. DOI 10.1093/jac/dki425 (Pubitemid 43057051)
68. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004;54:821-3. (Pubitemid 39386738)
69. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell divisiontype efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001;45: 3375-80. DOI 10.1128/AAC.45.12.3375-3380.2001 (Pubitemid 33107849)
70. Costa SF, Woodcock J, Gill M, et al. Outer-membrane proteins pattern and detection of beta-lactamases in clinical isolates of imipenem-resistant Acinetobacter baumannii from Brazil. Int J Antimicrob Agents 2000;13:175-82.
71. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003;51:565-74. (Pubitemid 36336148)
72. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother 2005;49:1432-40. DOI 10.1128/AAC.49.4.1432-1440.2005 (Pubitemid 40463373)
73. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 2002;40:4776-8. (Pubitemid 35434989)
74. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000;38:3299-305.
75. Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherapy 1991;37:405-12.
76. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 2007;59:1001-4. DOI 10.1093/jac/dkm058 (Pubitemid 47073374)
77. Siroy A, Molle V, Lemaitre-Guillier C, et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:4876-83. DOI 10.1128/AAC.49.12. 4876-4883.2005 (Pubitemid 41778897)
78. Dupont M, Pages JM, Lafitte D, Siroy A, Bollet C. Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res 2005;4:2386-90. DOI 10.1021/pr050143q (Pubitemid 41814312)
79. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60. DOI 10.1128/MMBR.65.2.232-260.2001 (Pubitemid 32538179)
80. Yan ZQ, Shen DX, Cao JR, et al. Susceptibility patterns and molecular epidemiology of multidrug-resistant Acinetobacter baumannii strains from three military hospitals in China. Int J Antimicrob Agents 2010;35: 269-73. DOI 10.1016/j.ijantimicag.2009.10.016
81. Mak JK, Kim MJ, Pham J, Tapsall J, White PA. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2009;63:47-54. DOI 10.1093/jac/dkn454
82. Guardabassi L, Dijkshoorn L, Collard JM, Olsen JE, Dalsgaard A. Distribution and in-vitro transfer of tetracycline resistance determinants in clinical and aquatic Acinetobacter strains. J Med Microbiol 2000;49:929-36.
83. Huys G, Cnockaert M, Nemec A, et al. Repetitive-DNA-element PCR fingerprinting and antibiotic resistance of pan-European multi-resistant Acinetobacter baumannii clone III strains. J Med Microbiol 2005;54: 851-6. DOI 10.1099/jmm.0.45986-0 (Pubitemid 41216281)
84. Ribera A, Ruiz J, Vila J. Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii. Antimicrob Agents Chemother 2003;47:2310-2. (Pubitemid 36753589)
85. Huys G, Cnockaert M, Vaneechoutte M, et al. Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant Acinetobacter baumannii strains from different European hospitals. Res Microbiol 2005;156:348-55. DOI 10.1016/j.resmic.2004.10.008 (Pubitemid 40487456)
86. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 2000;6:277-82. (Pubitemid 32141463)
87. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 2004;48:3298-304. DOI 10.1128/AAC.48.9.3298-3304.2004 (Pubitemid 39129322)
88. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 2008;52:2999-3005. DOI 10.1128/AAC.01684-07
89. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:2065-9. DOI 10.1128/AAC.01198-06 (Pubitemid 46903095)
90. Damier-Piolle L, Magnet S, Bremont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52:557-62. DOI 10.1128/AAC.00732-07 (Pubitemid 351170828)
91. Arroyo LA, Mateos I, Gonzalez V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug- resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009;53:1295-6. DOI 10.1128/AAC.01097-08
92. Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 2010;66:187-94. DOI 10.1016/j.diagmicrobio.2009.09.012
93. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6. DOI 10.1128/AAC.01099-06
94. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(suppl 5):S315-32. DOI 10.1086/431673
95. Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87. (Pubitemid 34223669)
96. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400-4. (Pubitemid 36070396)
97. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84. DOI 10.1128/AAC.01464-06 (Pubitemid 47519332)
98. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol 2008;46:2499-507. DOI 10.1128/JCM.00367-08
99. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704. DOI 10.1111/j.1469-0691. 2004.00942.x (Pubitemid 39232684)
100. Hamouda A, Amyes SG. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Chemother 2004;54:695-6. DOI 10.1093/jac/dkh368 (Pubitemid 39263916)
101. Vila J, Ruiz J, Goni P, Marcos A, Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995;39:1201-3.
102. Vila J, Ruiz J, Goni P, Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997;39:757-62. (Pubitemid 27296416)
103. Spence RP, Towner KJ. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003;52:687-90. DOI 10.1093/jac/dkg424 (Pubitemid 37258434)
104. Wisplinghoff H, Decker M, Haefs C, Krut O, Plum G, Seifert H. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J Antimicrob Chemother 2003;51:177-80. (Pubitemid 36163847)
105. Yin XL, Hou TW, Xu SB, et al. Detection of drug resistance-associated genes of multidrug-resistant Acinetobacter baumannii. Microb Drug Resist 2008;14:145-50. DOI 10.1089/mdr.2008.0799
106. Srinivasan VB, Rajamohan G, Pancholi P, et al. Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA. Ann Clin Microbiol Antimicrob 2009;8:21. DOI 10.1186/1476-0711-8-21
107. Wieczorek P, Sacha P, Hauschild T, Zorawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii - the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol 2008;46:257-67. DOI 10.2478/v10042-008-0056-x
108. Su XZ, Chen J, Mizushima T, Kuroda T, Tsuchiya T. AbeM, an H+- coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob Agents Chemother 2005;49:4362-4. DOI 10.1128/AAC.49.10.4362-4364.2005 (Pubitemid 41400988)
109. Cho YJ, Moon DC, Jin JS, Choi CH, Lee YC, Lee JC. Genetic basis of resistance to aminoglycosides in Acinetobacter spp. and spread of armA in Acinetobacter baumannii sequence group 1 in Korean hospitals. Diagn Microbiol Infect Dis 2009;64:185-90. DOI 10.1016/j.diagmicrobio.2009.02.010
110. Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global spread of multiple aminoglycoside resistance genes. Emerg Infect Dis 2005;11:951-3. (Pubitemid 40720861)
111. Vila J, Ruiz J, Navia M, et al. Spread of amikacin resistance in Acinetobacter baumannii strains isolated in Spain due to an epidemic strain. J Clin Microbiol 1999;37:758-61. (Pubitemid 29091298)
112. Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol 2004;53:1233-40. DOI 10.1099/jmm.0.45716-0 (Pubitemid 40052479)
113. Seward RJ, Lambert T, Towner KJ. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J Med Microbiol 1998;47:455-62. (Pubitemid 28191050)
114. Smith CA, Baker EN. Aminoglycoside antibiotic resistance by enzymatic deactivation. Curr Drug Targets Infect Disord 2002;2:143-60.
115. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006;70:140-50. DOI 10.1007/s00253-005- 0279-0
116. Lambert T, Gerbaud G, Courvalin P. Transferable amikacin resistance in Acinetobacter spp. due to a new type of 3′-aminoglycoside phosphotransferase. Antimicrob Agents Chemother 1988;32:15-9. (Pubitemid 18025669)
117. Nemec A, Maixnerova M, van der Reijden TJ, van den Broek PJ, Dijkshoorn L. Relationship between the AdeABC efflux system gene content, netilmicin susceptibility and multidrug resistance in a genotypically diverse collection of Acinetobacter baumannii strains. J Antimicrob Chemother 2007;60:483-9. DOI 10.1093/jac/dkm231 (Pubitemid 47299860)
118. Appleman MD, Belzberg H, Citron DM, et al. In vitro activities of non-traditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000;44:1035-40.
119. Fernandez Cuenca F, Pascual A, Martinez Martinez L, Perea EJ. [In vitro activity of azithromycin against clinical isolates of Acinetobacter baumannii]. Rev Esp Quimioter 2003;16:204-8.
120. Fass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993;37:2080-6. (Pubitemid 23298193)
121. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12:315-21. DOI 10.1111/j.1469-0691.2005. 01351.x
122. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug- resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50. DOI 10.1128/AAC.00103-06 (Pubitemid 44396396)
123. Conrad RS, Galanos C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob Agents Chemother 1989;33:1724-8. (Pubitemid 19239164)
124. Young ML, Bains M, Bell A, Hancock RE. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother 1992;36:2566-8.
125. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobactor baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34.
126. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2007;51:3413-5. DOI 10.1128/AAC.01571-06 (Pubitemid 350067568)